Jeff Aronin Provides Innovative Care To Patients

Jeff Aronin discovered his passion for innovative healthcare early in his career when he shadowed a physician who treated a child who suffered from seizures. Faced with the decision to either perform a complicated brain operation or to address it through medications first and to save the surgery if the treatment is unsuccessful, the physician opted for the medicine. Not only did this medication make the surgery unnecessary, but it also improved the child’s condition. This experience with the physician inspired Aronin to become an entrepreneur in the biopharmaceutical industry.


With a Bachelor’s Degree from Northern Illinois University in DeKalb, Illinois and a Master of Business Administration from DePaul University in Chicago Illinois, Jeff Aronin has earned a reputation as one of the top founders in the field of health and biotech industry with over 20 years of experience in healthcare innovation. Feeling that he can do more for patients with complicated, neglected and unmet medical needs, he started the pharmaceutical company Ovation Pharmaceuticals LLC in 2000 where he also served as the CEO. This company, with its focus on the patients’ needs, brought new innovative treatments through drug development and submitting it for approval by the Food and Drug Administration. In 2009, Lundbeck, a Danish pharmaceutical company, bought Ovation Pharmaceuticals for $900 million while keeping Aronin as the CEO until 2010.


In 2010 Jeff Aronin, continuing to work in the pharmaceutical industry with his passion for science and healthcare, became the Chairman and CEO of the innovative biotech company Paragon Biosciences. This company, comprised of top-notch talent, provides new medications to the pharmaceutical market while focusing on cutting-edge science, the unmet medical needs of patients, and creating a community of entrepreneurs with a common goal. The management and leadership team of Paragon Biosciences brought essential medicines to the market and secured 13 approvals from the Food and Drug Administration through using their enterprising skills.